Disclosed herein is a batch of ocular microimplants, each microimplant having a diameter of 0.483 mm (0.019 inches) or less and comprising a homogeneous mixture of one or more active ingredients, a bioerodible polylactic acid-polyglycolic acid copolymer and a bioerodible polylactic acid-polyglycolic acid copolymer having a free acid end group, wherein the batch has a relative mass standard deviation of 2 [%] or less, wherein each microimplant has a diameter of 0.381 mm or less, and wherein each microimplant has a length of 10 mm or less, and wherein said active ingredient is an anti-inflammatory agent selected from the group consisting of cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone, and wherein said one or morebioerodible polymers is a polylactic acid polyglycolic acid (PLGA) copolymer or a mixture of a polylactic acid polyglycolic acid (PLGA) copolymer and a polylactic acid polyglycolic acid (PLGA) copolymer having a free acid end.
